Combination Therapy of HAIC, Sintilimab and Bevacizumab for Advanced Hepatocellular Carcinoma
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
This is a single-arm, exploratory study to evaluate the efficacy and safety of HAIC in
combination with sintilimab and bevacizumab in the first line treatment of patients with
BCLC-C hepatocellular carcinoma.